Nasdaq:SLXN

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer ChemotherapiesSilexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA…

4 months ago
Silexion Therapeutics Announces 1-for-9 Reverse Share SplitSilexion Therapeutics Announces 1-for-9 Reverse Share Split

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech…

5 months ago
Silexion Therapeutics Announces 1-for-9 Reverse Share SplitSilexion Therapeutics Announces 1-for-9 Reverse Share Split

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech…

5 months ago
Silexion Therapeutics Announces 1-for-9 Reverse Share SplitSilexion Therapeutics Announces 1-for-9 Reverse Share Split

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech…

5 months ago